1 / 20

BREAST CANCER Oncology

BREAST CANCER Oncology. John Dewar. Breast Cancer. Commonest cancer in women 2 nd commonest cause of death from cancer in women Survival improving – 5 yr. survival improved from 56% 1970 to 79% in 1999 (year of diagnosis) Increasing incidence – ageing population. Presentation.

tsexton
Download Presentation

BREAST CANCER Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. BREAST CANCER Oncology John Dewar

  2. Breast Cancer • Commonest cancer in women • 2nd commonest cause of death from cancer in women • Survival improving – 5 yr. survival improved from 56% 1970 to 79% in 1999 (year of diagnosis) • Increasing incidence – ageing population

  3. Presentation • Screening – age 50-64(70), small, impalpable • Symptomatic – lump in breast 8% with distant metastases 8% locally advanced/inoperable 84% operable

  4. TREATMENT • Surgery • Radiotherapy • Systemic therapy hormonal therapy cytotoxic chemotherapy immunotherapy

  5. RADIOTHERAPY • Postoperatively to breast/chest wall nodal areas: axilla, supraclavicular fossa, internal mammary nodes • Primary radical for locally advanced • Palliatively to painful bony mets, skin deposits, brain mets etc.

  6. POSTOPERATIVE RADIOTHERAPY • Reduces the risk of local recurrence by about two thirds: 60% to 20% 30% to 10% 3% to 1%

  7. POSTOPERATIVE RADIOTHERAPY • All patients being treated conservatively (wide local excision/lumpectomy) • Mastectomy patients selectively – large tumour, extensive nodal involvement, involved margins etc.

  8. Postoperative Radiotherapy – acute side effects • Skin erythema to moist desquamation • Tiredness • Dysphagia if irradiating supraclavicular fossa • No alopecia

  9. Postoperative Radiotherapy – late effects • Local fibrosis and telangectasia • Lung fibrosis (rarely symptomatic) • Cardiac damage (ischaemic heart disease) – rarer now treatment better planned

  10. Postoperative Radiotherapy – late effects • Survival • Overall 5% improvement in breast cancer survival (at 15 yrs.) for 20% improvement in local control (4% improvement in overall survival) • Localised local recurrence can act as nidus for distant metastases

  11. SYSTEMIC THERAPY – adjuvant • Most operable, why not curable? • Occult distant metastases at presentation • Systemic therapy after surgery reduces the risk of recurrence and death – adjuvant therapy

  12. SYSTEMIC THERAPY – adjuvant • Hormone therapy: ovarian ablation, tamoxifen, aromatase inhibitors (ER/Pg +ve patients only) • Cytotoxic chemotherapy: CMF, doxirubicin/epirubicin, taxanes • Trastuzumab [Herceptin] • All decrease odds of death by about 17%, absolute benefit of about 6% at 10 years.

  13. Hormone therapy: Infertility Menopausal symptoms Weight gain Endometrial cancer Deep venous thrombosis Chemotherapy Nausea & vomiting Infertility Alopecia Neutropenia (sepsis) Mouth ulcers Lassitude SYSTEMIC THERAPY – adjuvant: side effects

  14. METASTATIC DISEASE • Incurable but treatable • Optimise quality of life and survival • Median survival with mets: 2 years (20% at 5 yrs.) • Varies from acute aggressive disease to chronic disease (like diabetes, renal failure etc.)

  15. METASTATIC DISEASE • Assess extent of disease Stage: local recurrence, lung, liver, bone • Hormone receptor status • HER2 receptor status

  16. METASTATIC DISEASELocal problems • Palliative radiotherapy: bony mets, brain mets etc. • Drainage of pleural or peritoneal effusions • Pining of pathological fractures

  17. METASTATIC DISEASE Systemic therapy • Hormone therapy if ER/Pg +ve • Chemotherapy • Bisphosphonates for bony mets • Trastuzumab if HER2 +ve

  18. METASTATIC DISEASE Systemic therapy • ER +ve: Hormonal agents: ovarian ablation, aromatase inhibitors, tamoxifen, progestagens in sequence unless liver mets or lymphangitis carcinomatosa when usually chemotherapy

  19. METASTATIC DISEASE • Chemotherapy: CMF, anthracyclines, taxanes, capcitabine etc. etc. • Use in sequence so long as respond and patient fit

  20. BREAST CANCER • Need multidisciplinary management: nurses, surgeons, radiologists, pathologists, oncologists, GP. etc. etc. • Different patients have different needs • Most will need considerable support • Major impact on the patients but also their families

More Related